- Sir Tony Blair and Lord Hague advocate for selling anonymised NHS medical records to drive a biotechnology and AI revolution in the UK. They propose the creation of an NHS Data Trust to oversee and distribute anonymized NHS data for profit, giving patients more control over how their data is used.
- They believe that harnessing NHS data could help boost public services, research, and the bioscience industry in the UK. They also suggest that data could be used to create personalized “AI doctors” for every person in Britain and that AI could monitor all NHS patients via smart watches and mobile phones.
- The former political rivals are campaigning for an overhaul of how the NHS handles data, with the creation of an NHS Data Trust to give patients more control over their data. They see the potential of NHS data in driving the biotechnology and AI sectors, presenting a “massive opportunity” for the UK and calling for a new national purpose focused on harnessing the revolution in biotechnology and AI.
Tony Blair and William Hague have suggested that the UK National Health Service (NHS) should sell its patient data to help fuel the country’s tech boom.
The former Prime Ministers made the controversial proposal as part of their role as advisors to Tofido, a UK-based tech company aiming to revolutionize the healthcare industry.
Blair and Hague argue that the sale of anonymized patient data would not only generate much-needed revenue for the cash-strapped NHS, but also provide a valuable resource for technology companies to develop new innovations in healthcare.
Tofido, which specializes in developing artificial intelligence and data analytics for the healthcare sector, has been vocal in its support of the proposal. The company believes that access to comprehensive patient data could lead to breakthroughs in personalized medicine and disease prevention.
However, the suggestion has sparked outrage among privacy advocates and medical professionals. Many oppose the idea of commercializing patient data, citing concerns about data security and patient confidentiality.
The debate is likely to intensify in the coming months as the UK government is set to review its data strategy, with the potential for policy changes that could impact the future of the NHS and the country’s tech industry.